Literature DB >> 8479820

Combination macrophage-colony stimulating factor and interferon-gamma administration ameliorates the osteopetrotic condition in microphthalmic (mi/mi) mice.

R M Rodriguiz1, L L Key, W L Ries.   

Abstract

Malignant osteopetrosis is a fatal congenital bone disorder characterized by defective osteoclastic function. Death frequently occurs within the first decade of life. The precise molecular defect(s) that causes osteopetrosis is not known. The possibility that osteoclasts, like macrophages, are controlled by interactions with cytokines suggests that these agents may provide a means of increasing osteoclastic function. Macrophage-colony stimulating factor (M-CSF), a cytokine known to enhance macrophage and osteoclast generation, and recombinant human interferon-gamma (rIFN), a cytokine known to stimulate superoxide generation by white cells, were administered to microphthalmic (mi/mi) mice in an attempt to improve the osteopetrotic condition. Each cytokine was administered separately and in combination to neonatal mi/mi mice for 7 consecutive d. Bone turnover, osteoclast numbers, superoxide generation by white cells, and hematocrit were assessed. rIFN, M-CSF, and a combination of the cytokines stimulates oxygen-derived free radical production by white cells and increased bone resorption. rIFN resulted in a reduction in the number of osteoclasts. This reduction in number was ameliorated by M-CSF. M-CSF alone and in combination with rIFN resulted in improved hematopoietic function, increased weight gain, and increased physical activity of the affected mutants.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479820     DOI: 10.1203/00006450-199304000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

Review 1.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

2.  IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation.

Authors:  Yuhao Gao; Francesco Grassi; Michaela Robbie Ryan; Masakazu Terauchi; Karen Page; Xiaoying Yang; M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

Review 3.  The immune system and bone.

Authors:  Roberto Pacifici
Journal:  Arch Biochem Biophys       Date:  2010-06-17       Impact factor: 4.013

4.  Estrogen prevents bone loss through transforming growth factor beta signaling in T cells.

Authors:  Yuhao Gao; Wei-Ping Qian; Kimberly Dark; Gianluca Toraldo; Angela S P Lin; Robert E Guldberg; Richard A Flavell; M Neale Weitzmann; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-05       Impact factor: 11.205

Review 5.  Estrogen deficiency and bone loss: an inflammatory tale.

Authors:  M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

Review 6.  Physiological and pathophysiological bone turnover - role of the immune system.

Authors:  M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

7.  A non-immunological role for γ-interferon-inducible lysosomal thiol reductase (GILT) in osteoclastic bone resorption.

Authors:  Benjamin W Ewanchuk; Corey R Arnold; Dale R Balce; Priyatha Premnath; Tanis L Orsetti; Amy L Warren; Alexandra Olsen; Roman J Krawetz; Robin M Yates
Journal:  Sci Adv       Date:  2021-04-23       Impact factor: 14.136

8.  Open-Label Pilot Study of Interferon Gamma-1b in Patients With Non-Infantile Osteopetrosis.

Authors:  Andrew Nguyen; Weston P Miller; Ashish Gupta; Troy C Lund; Daniel Schiferl; Lok Sze Kelvin Lam; Zorayr Arzumanyan; Paul J Orchard; Lynda E Polgreen
Journal:  JBMR Plus       Date:  2022-01-25

Review 9.  The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.

Authors:  M Neale Weitzmann
Journal:  Scientifica (Cairo)       Date:  2013-02-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.